vimarsana.com
Home
Live Updates
Eisai publishes additional detailed analyses from lecanemab
Eisai publishes additional detailed analyses from lecanemab
Eisai publishes additional detailed analyses from lecanemab phase 2b study (1)
STOCKHOLM, March 31, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
Related Keywords
Japan ,
Sweden ,
Stockholm ,
Uppsala ,
Uppsala Lan ,
China ,
Swedish ,
Oskar Bosson ,
Devices Agency ,
European Medicines Agency ,
Ministry Of Health ,
Drug Administration ,
National Institutes Of Health ,
Washington University School Of Medicine ,
Vp Communications ,
Alzheimer Network Trials Unit ,
Alzheimer Research Therapy ,
Alzheimer Clinical Trial Consortium ,
National Institute On ,
National Medical Products Administration ,
Uppsala University ,
Nasdaq Stockholm ,
Clinical Dementia Rating Sum Of Boxes ,
Scale Cognitive Subscale ,
Positron Emission Tomography ,
Brand Name ,
Clinical Trials ,
New England Journal ,
Biologics License Application ,
Priority Review ,
Prescription Drug User Fee Act ,
Medical Devices Agency ,
Clinical Trial Consortium ,
National Institute ,
National Institutes ,
Tau Nexgen ,
Dominantly Inherited ,
Washington University School ,
Commercialization Agreement ,
Nasdaq Stockholm Large Cap ,